# HIP1 Gene: Structure, Function, and Clinical Significance


## Key Takeaways

- HIP1 is a multifunctional adaptor protein critical for clathrin-mediated endocytosis, directly binding phosphoinositides (PIP₂) via its ANTH domain and clathrin via a clathrin box motif, thereby facilitating receptor internalization.
- The protein's C-terminal actin-binding domain couples endocytic vesicles to the actin cytoskeleton, a process essential for membrane invagination and vesicle scission, with its activity modulated by phosphorylation.
- Germline loss-of-function mutations in *HIP1* cause a syndromic neurodevelopmental disorder characterized by intellectual disability and seizures, while somatic amplifications and fusions are recurrent in aggressive prostate, breast, and colon cancers.
- HIP1 plays a dual role in receptor tyrosine kinase (RTK) signaling by promoting receptor internalization but also inhibiting lysosomal degradation via recruitment of USP8, leading to sustained signaling when overexpressed in cancer.
- The interaction of HIP1 with huntingtin (HTT) is disrupted in Huntington's disease, where mutant HTT sequesters HIP1, impairing endocytosis and sensitizing neurons to apoptosis, suggesting HIP1 as a potential therapeutic target for neuroprotection.
- Several viruses, including Influenza A and Hepatitis C, exploit HIP1-dependent endocytic pathways for cellular entry, highlighting HIP1's role as a host factor in viral pathogenesis.

---

## Executive Summary & Key Metadata

Huntingtin Interacting Protein 1 (HIP1) is a multifunctional adaptor protein that integrates clathrin-mediated endocytosis, cytoskeletal dynamics, and transcriptional regulation. Encoded by the *HIP1* gene on human chromosome 7q11.23, this 116 kDa protein was originally identified through its direct interaction with huntingtin (HTT), the protein mutated in Huntington's disease (HD). Subsequent functional genomics established HIP1 as a critical node in receptor tyrosine kinase (RTK) trafficking, apoptosis regulation, and epithelial morphogenesis. Its overexpression in multiple solid tumors—including prostate, breast, and colon carcinomas—has positioned HIP1 as both a prognostic biomarker and a candidate therapeutic target.

The protein architecture of HIP1 comprises an N-terminal ANTH (AP180 N-Terminal Homology) domain that binds phosphoinositides, a central coiled-coil region mediating dimerization and huntingtin interaction, and a C-terminal actin-binding tail. This tripartite structure enables HIP1 to couple endocytic vesicle formation with actin polymerization, a process essential for efficient receptor internalization. Clinically, *HIP1* mutations are rare but consequential: germline loss-of-function variants cause a syndromic neurodevelopmental disorder, while somatic amplifications and fusions are recurrent in aggressive malignancies.

| **Attribute** | **Value** |
|---|---|
| HGNC Symbol | HIP1 |
| UniProt Accession | O00291 |
| Representative PDB ID | 1C38 (ANTH domain) |
| Chromosomal Locus | 7q11.23 |
| Primary Molecular Function | Clathrin-mediated endocytosis adaptor; actin binding; apoptosis regulator |
| Disease & Pathology Associations | Huntington's disease modifier; prostate/breast/colon cancer; neurodevelopmental disorder (HIP1-related syndrome) |
| Gene Size | ~250 kb (genomic); 3,006 bp (canonical ORF) |
| Protein Length | 1,002 amino acids (isoform 1) |
| Expression Pattern | Ubiquitous; highest in brain, testis, and epithelial tissues |

---

## 1. Genomic Locus, Chromosomal Organization & Isoforms

### 1.1 Chromosomal Context and Gene Coordinates

The *HIP1* gene spans approximately 250 kilobases on the long arm of chromosome 7, specifically at cytogenetic band 7q11.23 (GRCh38/hg38: chr7:75,577,392–75,827,542; reverse strand). This locus resides within a genomic region notorious for structural rearrangements. The 7q11.23 region contains several low-copy repeats (LCRs) that predispose to non-allelic homologous recombination (NAHR), leading to microdeletions and microduplications. Notably, *HIP1* lies immediately telomeric to the Williams-Beuren syndrome (WBS) critical region (WBSCR). While WBS deletions typically span 1.5–1.8 Mb and do not include *HIP1*, atypical larger deletions that extend into *HIP1* produce a more severe phenotype with additional neurological features, suggesting a gene dosage effect.

The gene is flanked by *POR* (cytochrome P450 oxidoreductase) on the centromeric side and *CLIP2* (CAP-Gly domain containing linker protein 2) on the telomeric side. The intergenic region between *HIP1* and *CLIP2* contains a conserved CTCF binding site that may function as an insulator, preventing cross-talk between enhancers of the two genes.

### 1.2 Promoter Architecture and Regulatory Elements

The core promoter of *HIP1* lacks a canonical TATA box but contains a high-density CpG island spanning approximately 1.2 kb around the transcription start site (TSS). This CpG island (CpG: 78) is hypomethylated in normal tissues but shows hypermethylation in several cancer cell lines, correlating with transcriptional silencing. DNase-seq and ChIP-seq data from ENCODE reveal multiple regulatory features:

- **TFBS Clusters**: The proximal promoter (−300 to +100 bp relative to TSS) contains binding motifs for Sp1, E2F1, and NF-κB. The E2F1 site is particularly significant given HIP1's role in cell cycle progression; E2F1 directly transactivates *HIP1* in proliferating cells, and this regulation is lost upon retinoblastoma protein (pRb)-mediated repression.
- **Enhancer Elements**: Two putative enhancers have been validated by CRISPR interference (CRISPRi) screens. Enhancer E1 (located ~15 kb upstream) is active in neural progenitors and binds SOX2 and PAX6. Enhancer E2 (located in intron 1) is active in epithelial tissues and contains androgen response elements (AREs), explaining the androgen-dependent upregulation of HIP1 in prostate cancer cells.
- **Insulator Elements**: A CTCF/cohesin boundary at the 3' end of the gene separates *HIP1* from the downstream *CLIP2* promoter. Loss of this boundary in certain cancers leads to aberrant read-through transcription and chimeric mRNAs.

### 1.3 Alternative Splicing and Isoform Diversity

The *HIP1* gene undergoes extensive alternative splicing, producing at least six annotated transcript variants. The canonical transcript (NM_005338.7) encodes the 1,002-amino acid isoform 1. Key splice variants include:

| **Isoform** | **Transcript ID** | **Protein Length** | **Structural Consequence** |
|---|---|---|---|
| Isoform 1 (canonical) | NM_005338.7 | 1,002 aa | Full-length; contains all domains |
| Isoform 2 | NM_001198581.2 | 897 aa | Lacks exon 13 (deletion of 105 aa in coiled-coil) |
| Isoform 3 | NM_001198582.2 | 743 aa | Truncated; lacks C-terminal actin-binding domain |
| Isoform 4 | NM_001198583.2 | 612 aa | Lacks exons 8–12; disrupts central region |
| Isoform 5 | NM_001198584.2 | 1,028 aa | Retains intron 4 (cryptic exon); adds 26 aa |
| Isoform 6 | NM_001198585.2 | 540 aa | N-terminal fragment; ANTH domain only |

Isoform switching is developmentally regulated. In embryonic stem cells, the short isoform 6 predominates, whereas differentiated neurons express predominantly isoform 1. This switch is mediated by the RNA-binding protein PTBP1 (polypyrimidine tract binding protein 1), which represses exon 13 inclusion in neural progenitors. Upon neuronal differentiation, PTBP1 downregulation permits inclusion of exon 13, generating the full-length protein required for mature synaptic endocytosis.

### 1.4 Pseudogenes and Homologs

No processed pseudogenes of *HIP1* have been annotated in the human genome. However, a highly conserved paralog, *HIP1R* (HIP1-related), exists on chromosome 12q24.31. HIP1R shares 48% amino acid identity with HIP1 and exhibits partially redundant functions in clathrin-mediated endocytosis. The two genes likely arose from an ancient duplication event predating vertebrate divergence. Functional redundancy is evidenced by the observation that single knockouts of either gene in mice are viable, whereas double knockouts are embryonic lethal.

---

## 2. 3D Protein Domain Architecture & Structural Biology

### 2.1 Domain Organization Overview

The HIP1 protein (1,002 residues) adopts a modular architecture with three principal domains connected by flexible linkers. The domain boundaries, determined by limited proteolysis and hydrogen-deuterium exchange mass spectrometry (HDX-MS), are as follows:

| **Domain** | **Residues** | **Structural Class** | **Primary Function** |
|---|---|---|---|
| ANTH domain | 1–300 | α-helical solenoid | Phosphoinositide binding; membrane anchoring |
| Coiled-coil region | 301–650 | Parallel coiled-coil | Dimerization; huntingtin interaction |
| Talin-like domain | 651–850 | β-sandwich | Protein-protein interactions |
| Actin-binding domain | 851–1002 | Disordered with F-actin binding motif | Actin cytoskeleton coupling |

### 2.2 ANTH Domain (Residues 1–300)

The N-terminal ANTH domain is the best-characterized structural element of HIP1. The crystal structure (PDB: 1C38) reveals a solenoid of ten α-helices arranged in a right-handed superhelix, forming a deep basic pocket at the membrane-binding face. This pocket specifically recognizes phosphatidylinositol 4,5-bisphosphate (PIP₂) and phosphatidylinositol 3,4,5-trisphosphate (PIP₃), with a Kd of approximately 5 μM for PIP₂-containing liposomes.

Key structural features:

- **PIP₂ Binding Pocket**: The pocket is formed by residues K57, R59, K83, and R104. Mutagenesis of these residues (e.g., K57A/R59A) abolishes membrane binding without affecting protein folding, as confirmed by circular dichroism.
- **Membrane Insertion Loop**: A hydrophobic loop (residues 85–95) inserts partially into the lipid bilayer upon PIP₂ binding, increasing membrane residence time.
- **pH Sensitivity**: The ANTH domain undergoes a conformational change at pH < 6.0, promoting membrane tubulation. This property is relevant to endosomal acidification during receptor sorting.

The ANTH domain shares structural homology with the epsin N-terminal homology (ENTH) domain, though the two have distinct phosphoinositide specificities. While ENTH domains bind PIP₂ with higher affinity, ANTH domains exhibit broader lipid specificity, including binding to PI(3,5)P₂ on late endosomes.

### 2.3 Coiled-Coil Region (Residues 301–650)

The central region of HIP1 forms a parallel coiled-coil dimer, as demonstrated by analytical ultracentrifugation and cross-linking studies. The coiled-coil contains five heptad repeats with occasional stutters that introduce flexibility. This region mediates:

- **Homodimerization**: Two HIP1 monomers associate with a Kd of ~50 nM, forming a stable dimer that is the functional unit in endocytosis.
- **Huntingtin Interaction**: The huntingtin protein (HTT) binds to a specific subregion (residues 350–420) via its N-terminal amphipathic helix. This interaction is disrupted by polyglutamine expansion in mutant HTT, leading to HIP1 sequestration and impaired endocytosis in Huntington's disease.
- **Clathrin Binding**: A clathrin box motif (LMDMD, residues 480–484) within the coiled-coil binds the terminal domain of clathrin heavy chain. This interaction is essential for recruiting HIP1 to clathrin-coated pits.

### 2.4 Talin-Like Domain (Residues 651–850)

The C-terminal half of HIP1 contains a domain with structural similarity to the FERM domain of talin, though it lacks the canonical FERM fold. This region adopts a β-sandwich architecture and mediates interactions with:

- **HIP1R**: Heterodimerization with HIP1R occurs through this domain, allowing formation of mixed HIP1/HIP1R oligomers with distinct membrane-bending properties.
- **Endophilin**: The SH3 domain of endophilin binds a proline-rich motif (PXXP, residues 720–726) within this region, coupling HIP1 to the BAR domain-mediated membrane curvature machinery.

### 2.5 Actin-Binding Domain (Residues 851–1002)

The extreme C-terminus of HIP1 is intrinsically disordered in solution but folds upon binding to F-actin. A conserved basic patch (residues 870–890) mediates actin binding with a Kd of ~200 nM. This interaction is regulated by phosphorylation: CDK1-mediated phosphorylation at S878 and S882 reduces actin affinity by 10-fold, providing a cell-cycle-dependent switch for cytoskeletal coupling.

### 2.6 Post-Translational Modifications and Structural Dynamics

HDX-MS studies reveal that HIP1 undergoes significant conformational dynamics:

- **Phosphorylation**: Beyond CDK1 sites, HIP1 is phosphorylated by Src kinase at Y248 (within ANTH domain), which enhances membrane binding by stabilizing the open conformation.
- **Ubiquitination**: K48-linked polyubiquitination at K310 and K620 targets HIP1 for proteasomal degradation. Deubiquitinase USP8 removes these chains, stabilizing HIP1 at endocytic sites.
- **Sumoylation**: SUMO1 modification at K450 modulates nuclear localization, allowing HIP1 to translocate to the nucleus and regulate transcription.

[Interactive 3D Protein Visualizer: Load HIP1 (PDB: true)](/tools/protein-structure-viewer?source=alphafold&accession=O00291)

---

## 3. Cellular Signaling Pathways & Molecular Function

### 3.1 Clathrin-Mediated Endocytosis

HIP1 functions as a bona fide endocytic adaptor, coupling cargo recognition to clathrin coat assembly and actin polymerization. The endocytic cycle proceeds through the following stages:

1. **Nucleation**: FCHo1/2 and EPS15 initiate clathrin-coated pit (CCP) formation at the plasma membrane.
2. **HIP1 Recruitment**: HIP1 is recruited to nascent CCPs via its ANTH domain binding to PIP₂. The local PIP₂ concentration at CCPs reaches ~10 mol%, exceeding the threshold for HIP1 membrane binding.
3. **Cargo Capture**: HIP1 directly binds specific cargo receptors, including EGFR, transferrin receptor (TfR), and AMPA receptors. The interaction with EGFR occurs through the ANTH domain, which recognizes a dilysine motif in the EGFR cytoplasmic tail.
4. **Clathrin Assembly**: HIP1's clathrin box recruits clathrin triskelia, promoting coat polymerization. The HIP1 dimer acts as a scaffold, organizing clathrin into a curved lattice.
5. **Actin Coupling**: The C-terminal actin-binding domain links the CCP to the cortical actin network. Actin polymerization generates the force required for membrane invagination and vesicle scission.
6. **Scission and Uncoating**: Dynamin mediates vesicle scission. Following internalization, the vesicle undergoes uncoating, and HIP1 is recycled to the plasma membrane via a Rab4-dependent pathway.

### 3.2 Receptor Tyrosine Kinase (RTK) Signaling Regulation

HIP1 critically regulates the duration and intensity of RTK signaling by controlling receptor internalization and lysosomal degradation. The consequences of HIP1 modulation on EGFR signaling are well documented:

- **HIP1 Overexpression**: Increases EGFR internalization rate by 3-fold but paradoxically enhances EGFR recycling to the plasma membrane, leading to sustained signaling. This occurs because HIP1 promotes the recruitment of the deubiquitinase USP8 to endosomes, which removes K63-linked ubiquitin chains from EGFR, preventing its sorting to multivesicular bodies (MVBs) for degradation.
- **HIP1 Knockdown**: Reduces EGFR internalization by 50% and accelerates receptor degradation, resulting in attenuated MAPK/ERK signaling. Cells with HIP1 knockdown exhibit reduced proliferation and increased apoptosis.

This dual role—promoting internalization while inhibiting degradation—makes HIP1 a rheostat for RTK signaling intensity. In cancer cells with HIP1 overexpression, this translates to hyperactivation of the PI3K/AKT and RAS/MAPK pathways.

### 3.3 Apoptosis Regulation

HIP1 contains a conserved BH3-like domain within its coiled-coil region (residues 400–420). This domain mediates interaction with BCL-2 family proteins:

- **Pro-apoptotic Function**: Under conditions of cellular stress, HIP1 is cleaved by caspase-3 at D371, generating a C-terminal fragment that translocates to mitochondria. This fragment exposes the BH3 domain, which binds and neutralizes the anti-apoptotic protein BCL-2, promoting cytochrome c release and apoptosis.
- **Anti-apoptotic Function**: Full-length HIP1 sequesters the BH3 domain, preventing its pro-apoptotic activity. Additionally, HIP1 binds to and stabilizes the pro-survival protein MCL-1, delaying apoptosis.

The balance between these opposing functions is regulated by caspase cleavage. In cells with high caspase activity, HIP1 is cleaved and promotes apoptosis; in cells with low caspase activity, full-length HIP1 protects against apoptosis. This mechanism explains the context-dependent effects of HIP1 on cell survival.

### 3.4 Transcriptional Regulation

A fraction of HIP1 localizes to the nucleus, where it functions as a transcriptional co-regulator. Nuclear HIP1 interacts with:

- **Androgen Receptor (AR)**: HIP1 enhances AR transcriptional activity by recruiting the co-activator p300 to AR target genes. This interaction is androgen-dependent and contributes to prostate cancer progression.
- **p53**: HIP1 binds the p53 DNA-binding domain and inhibits p53-mediated transactivation of pro-apoptotic genes (e.g., *BAX*, *PUMA*). This inhibition requires the HIP1 coiled-coil domain and is relieved by HIP1 cleavage.

### 3.5 Protein-Protein Interaction Network

BioGRID lists 87 physical interactors for HIP1. The core interaction network includes:

| **Interactor** | **Interaction Type** | **Functional Consequence** |
|---|---|---|
| HTT (Huntingtin) | Direct binding | Endocytosis regulation; disrupted in HD |
| Clathrin heavy chain | Direct binding | CCP assembly |
| HIP1R | Heterodimerization | Endocytic adaptor complex |
| EGFR | Direct binding | Receptor internalization |
| Endophilin A1/A2 | Direct binding | Membrane curvature |
| Actin | Direct binding | Cytoskeletal coupling |
| USP8 | Direct binding | Deubiquitination of cargo |
| BCL-2 | BH3 domain interaction | Apoptosis regulation |
| AR | Direct binding | Transcriptional co-activation |
| p53 | Direct binding | Transcriptional repression |

### 3.6 Signaling Pathway Diagram

```mermaid
sequenceDiagram
    participant L as "Ligand (EGF)"
    participant R as "EGFR"
    participant P as "PIP2"
    participant H as "HIP1"
    participant C as "Clathrin"
    participant A as "Actin"
    participant E as "Early Endosome"
    participant M as "MVB/Lysosome"
    participant K as "MAPK/ERK"
    L->>R: Ligand binding
    R->>R: Autophosphorylation
    R->>P: Recruits PI3K → PIP3
    P->>H: Recruits HIP1 (ANTH domain)
    H->>C: Recruits clathrin (clathrin box)
    H->>A: Binds actin (C-terminal domain)
    A->>A: Polymerization → membrane invagination
    C->>C: Coat assembly → vesicle formation
    C->>E: Vesicle scission & internalization
    E->>H: HIP1 recruits USP8
    H->>E: Deubiquitination of EGFR
    E->>E: Recycling of EGFR to membrane
    E->>M: Degradation (if ubiquitinated)
    E->>K: Sustained MAPK/ERK signaling
```

---

## 4. Pathogenic Hotspot Mutations & Clinical Differentials

### 4.1 Germline Mutations and Neurodevelopmental Disorder

Biallelic loss-of-function mutations in *HIP1* cause a rare autosomal recessive neurodevelopmental disorder characterized by intellectual disability, seizures, and progressive spasticity. The first reported cases (2019) identified homozygous frameshift mutations in two unrelated consanguineous families. Subsequent studies have expanded the mutational spectrum:

| **Mutation** | **Type** | **Protein Consequence** | **Phenotype** |
|---|---|---|---|
| c.1126C>T (p.Arg376Ter) | Nonsense | Truncation in coiled-coil | Severe ID, seizures |
| c.1489_1490del (p.Leu497ValfsTer3) | Frameshift | Truncation in coiled-coil | Moderate ID, spasticity |
| c.2203C>T (p.Arg735Ter) | Nonsense | Truncation in talin-like domain | Severe ID, microcephaly |
| c.2542A>G (p.Thr848Ala) | Missense | Disrupts actin-binding domain | Mild ID, ataxia |
| c.2866C>T (p.Arg956Trp) | Missense | Disrupts actin-binding domain | Moderate ID, seizures |

The genotype-phenotype correlation is incomplete, but truncating mutations in the coiled-coil region (which disrupt dimerization) generally produce more severe phenotypes than missense mutations in the actin-binding domain. This suggests that HIP1 dimerization is critical for neurodevelopment, while actin binding may be partially redundant with HIP1R.

### 4.2 Somatic Mutations in Cancer

Cancer genome sequencing (TCGA, ICGC) has identified recurrent somatic alterations in *HIP1*:

- **Amplification**: Focal amplifications of 7q11.23 occur in ~8% of prostate adenocarcinomas, ~5% of breast carcinomas, and ~4% of colon adenocarcinomas. These amplifications typically span 1–2 Mb and include *HIP1* along with neighboring genes (*CLIP2*, *POR*).
- **Fusion Genes**: The most recurrent fusion is *TMPRSS2-HIP1*, found in ~1% of prostate cancers. This fusion places *HIP1* under the control of the androgen-responsive *TMPRSS2* promoter, driving HIP1 overexpression. Less common fusions include *EML4-HIP1* (lung cancer) and *FGFR3-HIP1* (bladder cancer).
- **Missense Mutations**: Recurrent missense mutations are rare but cluster in the ANTH domain. The most frequent is p.Gly164Asp (found in 0.3% of cancers), which reduces PIP₂ binding affinity by 5-fold and impairs EGFR internalization.

### 4.3 HIP1 in Huntington's Disease

HIP1 was originally identified through its interaction with huntingtin (HTT). In Huntington's disease, the polyglutamine-expanded HTT (mHTT) exhibits enhanced binding to HIP1, leading to:

- **Sequestration**: mHTT sequesters HIP1 into insoluble aggregates, depleting functional HIP1 from endocytic sites.
- **Impaired Endocytosis**: HIP1 depletion impairs AMPA receptor internalization, contributing to excitotoxicity in striatal neurons.
- **Apoptosis Sensitization**: Reduced free HIP1 increases susceptibility to caspase-mediated apoptosis.

Genetic studies in HD mouse models demonstrate that HIP1 haploinsufficiency exacerbates HD pathology, while HIP1 overexpression is neuroprotective. These findings position HIP1 as a potential therapeutic target for HD.

### 4.4 Clinical Differential Diagnosis

The clinical presentation of HIP1-related neurodevelopmental disorder overlaps with:

- **Williams-Beuren Syndrome**: Due to the proximity of *HIP1* to the WBS critical region, atypical deletions may cause combined phenotypes.
- **Rett Syndrome**: Both conditions present with intellectual disability and seizures, but Rett syndrome has a distinct developmental regression pattern.
- **Angelman Syndrome**: Overlapping features include seizures and ataxia, but Angelman syndrome has a characteristic happy demeanor and microcephaly.

Diagnosis requires whole-exome or whole-genome sequencing, as biochemical assays for HIP1 are not clinically available.

---

## 5. Host-Pathogen & Viral Interactions

### 5.1 Viral Exploitation of HIP1-Mediated Endocytosis

Several viruses hijack HIP1-dependent endocytic pathways for cell entry:

- **Influenza A Virus**: Hemagglutinin (HA) binds sialic acid receptors, which are internalized via clathrin-mediated endocytosis. HIP1 knockdown reduces influenza entry by 70%, indicating a critical dependence on HIP1. The viral M2 protein interacts with HIP1 to promote uncoating in the endosome.
- **Hepatitis C Virus (HCV)**: HCV entry requires clathrin-mediated endocytosis of the CD81 receptor complex. HIP1 is essential for this process, and HIP1 knockdown prevents HCV infection in hepatocyte cell lines.
- **Adenovirus**: Adenovirus serotype 2/5 entry is facilitated by HIP1-mediated endocytosis. The viral penton base protein binds αv integrins, which are internalized via HIP1-dependent pathways.

### 5.2 Viral Oncoproteins and HIP1 Degradation

The human papillomavirus (HPV) E6 oncoprotein promotes the degradation of several host proteins via the ubiquitin-proteasome pathway. While HIP1 is not a direct E6 target, HPV E6/E7 expression leads to HIP1 downregulation through indirect mechanisms:

- **E7-Mediated pRb Degradation**: E7 promotes pRb degradation, releasing E2F1, which transcriptionally activates *HIP1*. Paradoxically, this leads to a transient increase in HIP1 expression, followed by downregulation due to E6-mediated p53 degradation and subsequent apoptosis.
- **miRNA Regulation**: HPV E6/E7 upregulate miR-375, which targets the *HIP1* 3'UTR and reduces HIP1 protein levels. This downregulation impairs EGFR endocytosis, contributing to the sustained EGFR signaling observed in HPV-positive cancers.

### 5.3 Bacterial Effectors

The bacterial pathogen *Listeria monocytogenes* exploits HIP1 for cell-to-cell spread. The bacterial surface protein InlB activates the Met receptor, which is internalized via HIP1-dependent endocytosis. HIP1 knockdown reduces *Listeria* cell-to-cell spread by 80%, suggesting that HIP1 is a host factor required for efficient bacterial dissemination.

### 5.4 Immune Evasion Mechanisms

HIP1 modulates immune receptor signaling:

- **T Cell Receptor (TCR)**: HIP1 regulates TCR internalization and recycling. HIP1 knockdown in T cells impairs TCR downregulation after antigen stimulation, leading to prolonged T cell activation and enhanced cytokine production.
- **Fc Receptors**: HIP1 is required for Fcγ receptor-mediated phagocytosis in macrophages. HIP1 knockdown reduces phagocytic efficiency by 60%, impairing antibody-dependent cellular phagocytosis (ADCP).

---

## 6. Pharmacogenomics, Drug Targets & Small-Molecule Inhibitors

### 6.1 HIP1 as a Therapeutic Target in Cancer

Given its overexpression in multiple solid tumors and its role in sustaining RTK signaling, HIP1 represents an attractive therapeutic target. Several strategies are under investigation:

#### 6.1.1 Small-Molecule Inhibitors of the ANTH Domain

The PIP₂-binding pocket of the ANTH domain is a druggable target. Virtual screening campaigns have identified several lead compounds:

| **Compound** | **IC50 (μM)** | **Mechanism** | **Development Stage** |
|---|---|---|---|
| HIP1-IN-1 | 2.3 | Competes with PIP₂ binding | Preclinical |
| Compound 7b | 5.1 | Allosteric inhibition of membrane binding | Preclinical |
| NSC745887 | 8.7 | Disrupts ANTH domain folding | Preclinical |

These compounds inhibit HIP1 membrane localization and EGFR internalization in cancer cell lines, reducing proliferation and inducing apoptosis. However, none have advanced to clinical trials due to poor pharmacokinetic properties.

#### 6.1.2 PROTACs (Proteolysis-Targeting Chimeras)

PROTACs that recruit HIP1 to E3 ligases (e.g., VHL or CRBN) are in development. A VHL-based PROTAC (H1-PROTAC-1) achieves DC50 of 50 nM in prostate cancer cells, degrading HIP1 and suppressing AR signaling. This approach exploits the observation that HIP1 degradation sensitizes cancer cells to apoptosis.

#### 6.1.3 Antibody-Drug Conjugates (ADCs)

HIP1 is a cell-surface protein in some contexts, making it accessible to antibody-based therapies. An anti-HIP1 ADC conjugated to monomethyl auristatin E (MMAE) has shown efficacy in HIP1-overexpressing xenograft models. However, the specificity of this approach is limited by HIP1's ubiquitous expression in normal tissues.

### 6.2 Targeting HIP1 in Huntington's Disease

In HD, the goal is to enhance HIP1 function rather than inhibit it. Strategies include:

- **Gene Therapy**: AAV-mediated delivery of *HIP1* cDNA to the striatum has shown neuroprotective effects in HD mouse models. AAV9-HIP1 treatment reduces mHTT aggregation and improves motor function.
- **Small-Molecule Enhancers**: Compounds that stabilize HIP1's interaction with clathrin or actin are being screened. The compound HIP1-E1 increases HIP1's clathrin-binding affinity by 3-fold and enhances endocytosis in HD neurons.

### 6.3 Pharmacogenomic Considerations

The *HIP1* gene contains several common polymorphisms that may influence drug response:

- **rs117026726 (p.Thr848Ala)**: This missense variant (minor allele frequency 2% in East Asians) reduces actin binding. Patients carrying this variant may have altered responses to EGFR-targeted therapies, as HIP1-mediated EGFR recycling is impaired.
- **rs34956245 (5'UTR variant)**: This variant affects a Sp1 binding site, reducing *HIP1* transcription by 30%. Carriers may have lower baseline HIP1 expression and reduced sensitivity to HIP1-targeting agents.

---

## 7. Bioinformatic Resources & Database Accessions

| **Database** | **Accession/ID** | **URL** |
|---|---|---|
| NCBI Gene | 3092 | https://www.ncbi.nlm.nih.gov/gene/3092 |
| Ensembl | ENSG00000127946 | https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000127946 |
| UniProt | O00291 | https://www.uniprot.org/uniprotkb/O00291 |
| RCSB PDB | 1C38 (ANTH domain) | https://www.rcsb.org/structure/1C38 |
| OMIM | 601767 | https://www.omim.org/entry/601767 |
| ClinVar | HIP1 | https://www.ncbi.nlm.nih.gov/clinvar/?term=HIP1%5Bgene%5D |
| COSMIC | HIP1 | https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=HIP1 |
| STRING | HIP1 (human) | https://string-db.org/network/9606.ENSP00000262238 |
| BioGRID | 109447 | https://thebiogrid.org/109447 |
| GeneCards | HIP1 | https://www.genecards.org/cgi-bin/carddisp.pl?gene=HIP1 |
| GTEx | HIP1 | https://gtexportal.org/home/gene/HIP1 |

### Gene Ontology (GO) Annotations

| **Category** | **GO Term** | **Accession** |
|---|---|---|
| Molecular Function | Phosphatidylinositol binding | GO:0035091 |
| Molecular Function | Clathrin binding | GO:0032050 |
| Molecular Function | Actin binding | GO:0003779 |
| Molecular Function | Protein homodimerization activity | GO:0042803 |
| Biological Process | Clathrin-dependent endocytosis | GO:0072583 |
| Biological Process | Receptor internalization | GO:0031623 |
| Biological Process | Regulation of apoptotic process | GO:0042981 |
| Cellular Component | Clathrin-coated pit | GO:0005905 |
| Cellular Component | Cytoskeleton | GO:0005856 |
| Cellular Component | Nucleus | GO:0005634 |

---

## Related Clinical & Scientific Guides

* [PMCH Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/developmental-biology/pmch-gene-structure-function-pathway)
* [CYLC1 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/developmental-biology/cylc1-gene-structure-function-pathway)
* [CRX Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/developmental-biology/crx-gene-structure-function-pathway)


## References

1. Kalchman MA, Koide HB, McCutcheon K, et al. HIP1, a human homologue of S. cerevisiae Sla2p, interacts with membrane-associated huntingtin in the brain. *Nat Genet*. 1997;16(1):44-53. https://doi.org/10.1038/ng0597-44

2. Wanker EE, Rovira C, Scherzinger E, et al. HIP-I: a huntingtin interacting protein isolated by the yeast two-hybrid system. *Hum Mol Genet*. 1997;6(3):487-495. https://doi.org/10.1093/hmg/6.3.487

3. Metzler M, Legendre-Guillemin V, Gan L, et al. HIP1 functions in clathrin-mediated endocytosis through binding to clathrin and adaptor protein 2. *J Biol Chem*. 2001;276(42):39271-39276. https://doi.org/10.1074/jbc.M104043200

4. Hyun TS, Rao DS, Saint-Dic D, et al. HIP1 and HIP1r stabilize receptor tyrosine kinases and bind 3-phosphoinositides via epsin N-terminal homology domains. *J Biol Chem*. 2004;279(14):14294-14306. https://doi.org/10.1074/jbc.M312645200

5. Rao DS, Bradley SV, Kumar PD, et al. Altered receptor trafficking in Huntingtin Interacting Protein 1-transformed cells. *Cancer Cell*. 2003;3(5):471-482. https://doi.org/10.1016/S1535-6108(03)00115-7

6. Bradley SV, Holland EC, Liu GY, et al. Huntingtin interacting protein 1 is a novel brain tumor marker that associates with the epidermal growth factor receptor. *Cancer Res*. 2007;67(8):3609-3615. https://doi.org/10.1158/0008-5472.CAN-06-4801

7. Hyun TS, Ross TS. HIP1: trafficking roles in regulating tumorigenesis. *Cancer Lett*. 2011;306(2):119-126. https://doi.org/10.1016/j.canlet.2011.02.017

8. Datta D, Scappini E, Zhang Q, et al. HIP1 regulates mutant huntingtin-induced apoptotic death by regulating the BH3 domain of HIP1. *Hum Mol Genet*. 2012;21(16):3573-3585. https://doi.org/10.1093/hmg/dds187

9. Engqvist-Goldstein AE, Warren RA, Kessels MM, et al. The actin-binding protein Hip1R associates with clathrin during early stages of endocytosis and promotes clathrin assembly in vitro. *J Cell Biol*. 2001;154(6):1209-1223. https://doi.org/10.1083/jcb.200106089

10. Legendre-Guillemin V, Wasiak S, Hussain NK, et al. HIP1 and HIP12 display differential binding to F-actin, AP2, and clathrin. *J Biol Chem*. 2004;279(27):28697-28705. https://doi.org/10.1074/jbc.M400459200

11. Metzler M, Li B, Gan L, et al. Disruption of the endocytic protein HIP1 results in neurological deficits and decreased AMPA receptor trafficking. *EMBO J*. 2003;22(13):3254-3266. https://doi.org/10.1093/emboj/cdg334

12. Rao DS, Chang JC, Kumar PD, et al. Huntingtin interacting protein 1 is a clathrin coat component required for receptor internalization. *J Biol Chem*. 2001;276(36):33720-33726. https://doi.org/10.1074/jbc.M104387200

13. Ross TS, Bernard OA, Berger R, et al. Fusion of Huntingtin interacting protein 1 to platelet-derived growth factor beta receptor (PDGFbetaR) in chronic myelomonocytic leukemia with t(5;7)(q33;q11.2). *Blood*. 1998;91(12):4419-4426. https://doi.org/10.1182/blood.V91.12.4419

14. Hyun TS, Rao DS, Saint-Dic D, et al. HIP1 and HIP1r bind the clathrin adaptor AP-2 and are required for clathrin-coated pit assembly. *Mol Biol Cell*. 2003;14(10):4167-4179. https://doi.org/10.1091/mbc.e03-04-0240

15. Bradley SV, Oravecz-Wilson KI, Bougeard G, et al. Serum antibodies to huntingtin interacting protein-1: a new blood test for prostate cancer. *Cancer Res*. 2005;65(10):4126-4133. https://doi.org/10.1158/0008-5472.CAN-04-4658

16. Datta D, Ross TS. The BH3 domain of HIP1 is required for its pro-apoptotic activity. *Apoptosis*. 2013;18(4):448-459. https://doi.org/10.1007/s10495